{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T08:55:48Z","timestamp":1793350548166,"version":"4.5.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"8110","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2026,4,16]]},"DOI":"10.1038\/s41586-026-10197-0","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:01:19Z","timestamp":1772640079000},"page":"752-762","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Homologous recombination deficiency and hemizygosity\u00a0drive resistance in breast cancer"],"prefix":"10.1038","volume":"652","author":[{"given":"Anton","family":"Safonov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minna","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8249-3632","authenticated-orcid":false,"given":"David N.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Boscolo Bielo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0443-0625","authenticated-orcid":false,"given":"Miika","family":"Mehine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1108-4919","authenticated-orcid":false,"given":"Chaitanya","family":"Bandlamudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1092-9169","authenticated-orcid":false,"given":"Ben","family":"O\u2019Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8802-3033","authenticated-orcid":false,"given":"Laia","family":"Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Muldoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Ros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7310-7824","authenticated-orcid":false,"given":"Antonio","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier","family":"Selenica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Bieche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Wubbenhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Ferraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Courtois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania","family":"El Botty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehnaj","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4405-8357","authenticated-orcid":false,"given":"Enrico","family":"Moiso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Ah-Reum","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4538-6069","authenticated-orcid":false,"given":"Mark T. A.","family":"Donoghue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Will","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3748-8049","authenticated-orcid":false,"given":"Fresia","family":"Pareja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Nizialek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Lukashchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Sofianopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colombe","family":"Chappey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1328-1959","authenticated-orcid":false,"given":"Anna D.","family":"Staniszewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dara","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Mandelker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9055-7213","authenticated-orcid":false,"given":"Marc","family":"Ladanyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0131-4904","authenticated-orcid":false,"given":"Nikolaus","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3882-5000","authenticated-orcid":false,"given":"Michael F.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Scaltriti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge S.","family":"Reis-Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob T.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Offit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Norton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9694-584X","authenticated-orcid":false,"given":"Ronglai","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara N.","family":"Maxwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9417-9985","authenticated-orcid":false,"given":"Fergus","family":"Couch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5914-7272","authenticated-orcid":false,"given":"Susan M.","family":"Domchek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3337-6448","authenticated-orcid":false,"given":"Elisabetta","family":"Marangoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6402-523X","authenticated-orcid":false,"given":"Sohrab","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4406-6135","authenticated-orcid":false,"given":"Mark R.","family":"Albertella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6620-1065","authenticated-orcid":false,"given":"Violeta","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9927-1270","authenticated-orcid":false,"given":"Britta","family":"Weigelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6614-802X","authenticated-orcid":false,"given":"David B.","family":"Solit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6740-0901","authenticated-orcid":false,"given":"Katherine L.","family":"Nathanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3109-1692","authenticated-orcid":false,"given":"Mark E.","family":"Robson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8937-0873","authenticated-orcid":false,"given":"Nicholas C.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4532-8053","authenticated-orcid":false,"given":"Sarat","family":"Chandarlapaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4236-0576","authenticated-orcid":false,"given":"Pedram","family":"Razavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"10197_CR1","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc3599","volume":"13","author":"C Holohan","year":"2013","unstructured":"Holohan, C., Van Schaeybroeck, S., Longley, D. B. & Johnston, P. G. Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13, 714\u2013726 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"10197_CR2","doi-asserted-by":"publisher","unstructured":"Vasan, N., Baselga, J. & Hyman, D. M. A view on drug resistance in cancer. Nature https:\/\/doi.org\/10.1038\/s41586-019-1730-1 (2019).","DOI":"10.1038\/s41586-019-1730-1"},{"key":"10197_CR3","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41568-023-00604-3","volume":"23","author":"M Will","year":"2023","unstructured":"Will, M., Liang, J., Metcalfe, C. & Chandarlapaty, S. Therapeutic resistance to anti-oestrogen therapy in breast cancer. Nat. Rev. Cancer 23, 673\u2013685 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"10197_CR4","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","volume":"34","author":"P Razavi","year":"2018","unstructured":"Razavi, P. et al. The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell 34, 427\u2013438.e6 (2018).","journal-title":"Cancer Cell"},{"key":"10197_CR5","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1158\/2159-8290.CD-12-0012","volume":"2","author":"LA Garraway","year":"2012","unstructured":"Garraway, L. A. & J\u00e4nne, P. A. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov. 2, 214\u2013226 (2012).","journal-title":"Cancer Discov."},{"key":"10197_CR6","doi-asserted-by":"publisher","first-page":"747","DOI":"10.7326\/0003-4819-71-4-747","volume":"71","author":"FP Li","year":"1969","unstructured":"Li, F. P. & Fraumeni, J. F. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann. Intern. Med. 71, 747\u2013752 (1969).","journal-title":"Ann. Intern. Med."},{"key":"10197_CR7","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1126\/science.1978757","volume":"250","author":"D Malkin","year":"1990","unstructured":"Malkin, D. et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250, 1233\u20131238 (1990).","journal-title":"Science"},{"key":"10197_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/nature12477","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature https:\/\/doi.org\/10.1038\/nature12477 (2013).","journal-title":"Nature"},{"key":"10197_CR9","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1073\/pnas.68.4.820","volume":"68","author":"AG Knudson","year":"1971","unstructured":"Knudson, A. G. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl Acad. Sci. USA 68, 820\u2013823 (1971).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"10197_CR10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1126\/science.7545954","volume":"266","author":"Y Miki","year":"1994","unstructured":"Miki, Y. et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266, 66\u201371 (1994).","journal-title":"Science"},{"key":"10197_CR11","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/378789a0","volume":"378","author":"R Wooster","year":"1995","unstructured":"Wooster, R. et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 378, 789\u2013792 (1995).","journal-title":"Nature"},{"key":"10197_CR12","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/ng1959","volume":"39","author":"N Rahman","year":"2007","unstructured":"Rahman, N. et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat. Genet. 39, 165\u2013167 (2007).","journal-title":"Nat. Genet."},{"key":"10197_CR13","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJM198705213162101","volume":"316","author":"M Swift","year":"1987","unstructured":"Swift, M., Reitnauer, P. J., Morrell, D. & Chase, C. L. Breast and other cancers in families with ataxia-telangiectasia. N. Engl. J. Med. 316, 1289\u20131294 (1987).","journal-title":"N. Engl. J. Med."},{"key":"10197_CR14","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1086\/426403","volume":"75","author":"C Cybulski","year":"2004","unstructured":"Cybulski, C. et al. CHEK2 is a multiorgan cancer susceptibility gene. Am. J. Hum. Genet. 75, 1131\u20131135 (2004).","journal-title":"Am. J. Hum. Genet."},{"key":"10197_CR15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S1097-2765(01)00174-5","volume":"7","author":"ME Moynahan","year":"2001","unstructured":"Moynahan, M. E., Pierce, A. J. & Jasin, M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol. Cell 7, 263\u2013272 (2001).","journal-title":"Mol. Cell"},{"key":"10197_CR16","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S1097-2765(00)80202-6","volume":"4","author":"ME Moynahan","year":"1999","unstructured":"Moynahan, M. E., Chiu, J. W., Koller, B. H. & Jasint, M. Brca1 controls homology-directed DNA repair. Mol. Cell 4, 511\u2013518 (1999).","journal-title":"Mol. Cell"},{"key":"10197_CR17","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrc.2015.21","volume":"16","author":"CJ Lord","year":"2016","unstructured":"Lord, C. J. & Ashworth, A. BRCAness revisited. Nat. Rev. Cancer 16, 110\u2013120 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"10197_CR18","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917\u2013921 (2005).","journal-title":"Nature"},{"key":"10197_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf9246","volume":"8","author":"Y Pommier","year":"2016","unstructured":"Pommier, Y., O\u2019Connor, M. J. & De Bono, J. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Sci. Transl. Med. 8, 362ps17 (2016).","journal-title":"Sci. Transl. Med."},{"key":"10197_CR20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706450","author":"M Robson","year":"2017","unstructured":"Robson, M. et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa1706450 (2017).","journal-title":"N. Engl. J. Med."},{"key":"10197_CR21","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jama.2017.11137","volume":"318","author":"D Mandelker","year":"2017","unstructured":"Mandelker, D. et al. Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing. JAMA 318, 825\u2013835 (2017).","journal-title":"JAMA"},{"key":"10197_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2014.12.006","author":"DT Cheng","year":"2015","unstructured":"Cheng, D. T. et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT). J. Mol. Diagn. https:\/\/doi.org\/10.1016\/j.jmoldx.2014.12.006 (2015).","journal-title":"J. Mol. Diagn."},{"key":"10197_CR23","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nm.4333","volume":"23","author":"A Zehir","year":"2017","unstructured":"Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 23, 703\u2013713 (2017).","journal-title":"Nat. Med."},{"key":"10197_CR24","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s10549-017-4198-4","volume":"163","author":"J Krammer","year":"2017","unstructured":"Krammer, J. et al. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. Treat. 163, 565\u2013571 (2017).","journal-title":"Breast Cancer Res. Treat."},{"key":"10197_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1200\/JCO.2010.33.0068","volume":"30","author":"PJ Goodwin","year":"2012","unstructured":"Goodwin, P. J. et al. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an international prospective breast cancer family registry population-based cohort study. J. Clin. Oncol. 30, 19\u201326 (2012).","journal-title":"J. Clin. Oncol."},{"key":"10197_CR26","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.ejca.2006.12.009","volume":"43","author":"CTM Brekelmans","year":"2007","unstructured":"Brekelmans, C. T. M. et al. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1\/2 families as compared to sporadic breast cancer cases. Eur. J. Cancer 43, 867\u2013876 (2007).","journal-title":"Eur. J. Cancer"},{"key":"10197_CR27","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41467-017-00388-9","volume":"8","author":"KN Maxwell","year":"2017","unstructured":"Maxwell, K. N. et al. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers. Nat. Commun. 8, 319 (2017).","journal-title":"Nat. Commun."},{"key":"10197_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00921-w","volume":"8","author":"N Riaz","year":"2017","unstructured":"Riaz, N. et al. Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes. Nat. Commun. 8, 857 (2017).","journal-title":"Nat. Commun."},{"key":"10197_CR29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41523-019-0115-9","volume":"5","author":"A Li","year":"2019","unstructured":"Li, A. et al. Homologous recombination DNA repair defects in PALB2-associated breast cancers. npj Breast Cancer 5, 23 (2019).","journal-title":"npj Breast Cancer"},{"key":"10197_CR30","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1093\/jnci\/djy028","volume":"110","author":"B Weigelt","year":"2018","unstructured":"Weigelt, B. et al. The landscape of somatic genetic alterations in breast cancers from atm germline mutation carriers. J. Natl Cancer Inst. 110, 1030\u20131034 (2018).","journal-title":"J. Natl Cancer Inst."},{"key":"10197_CR31","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1158\/0008-5472.CAN-08-3426","volume":"69","author":"H Holstege","year":"2009","unstructured":"Holstege, H. et al. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Cancer Res. 69, 3625\u20133633 (2009).","journal-title":"Cancer Res."},{"key":"10197_CR32","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41523-019-0110-1","volume":"5","author":"B Na","year":"2019","unstructured":"Na, B. et al. Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation. npj Breast Cancer 5, 14 (2019).","journal-title":"npj Breast Cancer"},{"key":"10197_CR33","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/nm0797-721","volume":"3","author":"J Brugarolas","year":"1997","unstructured":"Brugarolas, J. & Jacks, T. Double indemnity: p53, BRCA and cancer. p53 mutation partially rescues developmental arrest in Brca1 and Brca2 null mice, suggesting a role for familial breast cancer genes in DNA damage repair. Nat. Med. 3, 721\u2013722 (1997).","journal-title":"Nat. Med."},{"key":"10197_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113198","volume":"42","author":"S Kim","year":"2023","unstructured":"Kim, S. et al. Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4\/6 inhibitors in breast cancer. Cell Rep. 42, 113198 (2023).","journal-title":"Cell Rep."},{"key":"10197_CR35","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1158\/2159-8290.CD-19-1390","volume":"10","author":"SA Wander","year":"2020","unstructured":"Wander, S. A. et al. The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4\/6 inhibitors in patients with hormone receptor-positive metastatic breast cancer. Cancer Discov. 10, 1174\u20131193 (2020).","journal-title":"Cancer Discov."},{"key":"10197_CR36","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi, G. N. et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N. Engl. J. Med. 375, 1738\u20131748 (2016).","journal-title":"N. Engl. J. Med."},{"key":"10197_CR37","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"M Cristofanilli","year":"2016","unstructured":"Cristofanilli, M. et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 17, 425\u2013439 (2016).","journal-title":"Lancet Oncol."},{"key":"10197_CR38","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz, M. P. et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J. Clin. Oncol. 35, 3638\u20133646 (2017).","journal-title":"J. Clin. Oncol."},{"key":"10197_CR39","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.ccell.2018.11.006","volume":"34","author":"Z Li","year":"2018","unstructured":"Li, Z. et al. Loss of the FAT1 tumor suppressor promotes resistance to CDK4\/6 inhibitors via the Hippo pathway. Cancer Cell 34, 893\u2013905.e8 (2018).","journal-title":"Cancer Cell"},{"key":"10197_CR40","doi-asserted-by":"publisher","unstructured":"Ma, X. et al. Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR. Preprint at medRXiv https:\/\/doi.org\/10.1101\/2020.03.16.20037143 (2023).","DOI":"10.1101\/2020.03.16.20037143"},{"key":"10197_CR41","unstructured":"Database characterization guide. Flatiron Health https:\/\/flatiron.com\/database-characterization (accessed 27 December 2025)"},{"key":"10197_CR42","doi-asserted-by":"publisher","first-page":"9603","DOI":"10.1073\/pnas.97.17.9603","volume":"97","author":"T Kainu","year":"2000","unstructured":"Kainu, T. et al. Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. Proc. Natl Acad. Sci. USA 97, 9603\u20139608 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"10197_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052079","volume":"7","author":"A Rouault","year":"2012","unstructured":"Rouault, A. et al. Deletion of chromosomes 13q and 14q is a common feature of tumors with BRCA2 mutations. PLoS ONE 7, e52079 (2012).","journal-title":"PLoS ONE"},{"key":"10197_CR44","doi-asserted-by":"crossref","unstructured":"Tsukamoto, K. et al. Two distinct commonly deleted regions on chromosome 13q suggest involvement of BRCA2 and retinoblastoma genes in sporadic breast carcinomas. Cancer 78, 1929\u20131934 (1996).","DOI":"10.1002\/(SICI)1097-0142(19961101)78:9<1929::AID-CNCR13>3.0.CO;2-#"},{"key":"10197_CR45","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.eururo.2017.02.023","volume":"72","author":"M Annala","year":"2017","unstructured":"Annala, M. et al. Treatment outcomes and tumor loss of heterozygosity in germline DNA repair-deficient prostate cancer. Eur. Urol. 72, 34\u201342 (2017).","journal-title":"Eur. Urol."},{"key":"10197_CR46","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1158\/1078-0432.CCR-19-4033","volume":"26","author":"AC Mandigo","year":"2020","unstructured":"Mandigo, A. C. & Knudsen, K. E. Double trouble: concomitant RB1 and BRCA2 depletion evokes aggressive phenotypes. Clin. Cancer Res. 26, 1784\u20131786 (2020).","journal-title":"Clin. Cancer Res."},{"key":"10197_CR47","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1158\/1078-0432.CCR-19-1570","volume":"26","author":"G Chakraborty","year":"2020","unstructured":"Chakraborty, G. et al. Significance of BRCA2 and RB1 co-loss in aggressive prostate cancer progression. Clin. Cancer Res. 26, 2047\u20132064 (2020).","journal-title":"Clin. Cancer Res."},{"key":"10197_CR48","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","volume":"379","author":"NC Turner","year":"2018","unstructured":"Turner, N. C. et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N. Engl. J. Med. 379, 1926\u20131936 (2018).","journal-title":"N. Engl. J. Med."},{"key":"10197_CR49","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41588-018-0165-1","volume":"50","author":"CM Bielski","year":"2018","unstructured":"Bielski, C. M. et al. Genome doubling shapes the evolution and prognosis of advanced cancers. Nat. Genet. 50, 1189\u20131195 (2018).","journal-title":"Nat. Genet."},{"key":"10197_CR50","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.annonc.2023.08.011","volume":"34","author":"F Andr\u00e9","year":"2023","unstructured":"Andr\u00e9, F. et al. Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials. Ann. Oncol. 34, 1003\u20131014 (2023).","journal-title":"Ann. Oncol."},{"key":"10197_CR51","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abq4293","volume":"8","author":"I Soria-Bretones","year":"2022","unstructured":"Soria-Bretones, I. et al. The spindle assembly checkpoint is a therapeutic vulnerability of CDK4\/6 inhibitor-resistant ER+ breast cancer with mitotic aberrations. Sci. Adv. 8, eabq4293 (2022).","journal-title":"Sci. Adv."},{"key":"10197_CR52","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1158\/2159-8290.CD-18-0469","volume":"9","author":"X Gong","year":"2019","unstructured":"Gong, X. et al. Aurora A kinase inhibition is synthetic lethal with loss of the RB1 tumor suppressor gene. Cancer Discov. 9, 248\u2013263 (2019).","journal-title":"Cancer Discov."},{"key":"10197_CR53","doi-asserted-by":"publisher","first-page":"5743","DOI":"10.1093\/nar\/gkw326","volume":"44","author":"S Ahrabi","year":"2016","unstructured":"Ahrabi, S. et al. A role for human homologous recombination factors in suppressing microhomology-mediated end joining. Nucleic Acids Res. 44, 5743\u20135757 (2016).","journal-title":"Nucleic Acids Res."},{"key":"10197_CR54","doi-asserted-by":"publisher","unstructured":"Gould, S. J. & Vrba, E. S. Exaptation \u2014 a missing term in the science of form. Paleobiology https:\/\/doi.org\/10.1017\/S0094837300004310 (1982).","DOI":"10.1017\/S0094837300004310"},{"key":"10197_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19406-4","volume":"11","author":"L Nguyen","year":"2020","unstructured":"Nguyen, L., Martens, J. W. M., Van Hoeck, A. & Cuppen, E. Pan-cancer landscape of homologous recombination deficiency. Nat. Commun. 11, 5584 (2020).","journal-title":"Nat. Commun."},{"key":"10197_CR56","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","volume":"379","author":"JK Litton","year":"2018","unstructured":"Litton, J. K. et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N. Engl. J. Med. 379, 753\u2013763 (2018).","journal-title":"N. Engl. J. Med."},{"key":"10197_CR57","doi-asserted-by":"publisher","first-page":"6708","DOI":"10.1158\/1078-0432.CCR-17-0544","volume":"23","author":"B Weigelt","year":"2017","unstructured":"Weigelt, B. et al. Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer. Clin. Cancer Res. 23, 6708\u20136720 (2017).","journal-title":"Clin. Cancer Res."},{"key":"10197_CR58","doi-asserted-by":"publisher","first-page":"P2-10-17","DOI":"10.1158\/1557-3265.SABCS24-P2-10-17","volume":"31","author":"P Razavi","year":"2025","unstructured":"Razavi, P. et al. Abstract P2-10-17: a randomized phase III study of first-line saruparib (AZD5305) + camizestrant vs CDK4\/6i plus physician\u2019s choice endocrine therapy or + camizestrant in patients w\/ BRCA1\/BRCA2\/PALB2 mutations & HR+\/HER2\u2212 advanced breast cancer (EvoPAR-Breast01). Clin. Cancer Res. 31, P2-10-17 (2025).","journal-title":"Clin. Cancer Res."},{"key":"10197_CR59","doi-asserted-by":"publisher","first-page":"4702","DOI":"10.1158\/1078-0432.CCR-22-1115","volume":"28","author":"C Febres-Aldana","year":"2022","unstructured":"Febres-Aldana, C. et al. Rb tumor suppressor in small cell lung cancer: combined genomic and IHC analysis with a description of a distinct Rb-proficient subset. Clin. Cancer Res. 28, 4702\u20134713 (2022).","journal-title":"Clin. Cancer Res."},{"key":"10197_CR60","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/ni.2526","volume":"14","author":"JI Youn","year":"2013","unstructured":"Youn, J. I. et al. Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat. Immunol. 14, 211\u2013220 (2013).","journal-title":"Nat. Immunol."},{"key":"10197_CR61","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1001\/jamaoncol.2015.5208","volume":"2","author":"KA Schrader","year":"2016","unstructured":"Schrader, K. A. et al. Germline variants in targeted tumor sequencing using matched normal DNA. JAMA Oncol. 2, 104\u2013111 (2016).","journal-title":"JAMA Oncol."},{"key":"10197_CR62","doi-asserted-by":"publisher","first-page":"6728","DOI":"10.1038\/s41467-022-34523-y","volume":"13","author":"JB Shah","year":"2022","unstructured":"Shah, J. B. et al. Analysis of matched primary and recurrent BRCA1\/2 mutation-associated tumors identifies recurrence-specific drivers. Nat. Commun. 13, 6728 (2022).","journal-title":"Nat. Commun."},{"key":"10197_CR63","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows\u2013Wheeler transform. Bioinformatics 25, 1754\u20131760 (2009).","journal-title":"Bioinformatics"},{"key":"10197_CR64","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw520","volume":"44","author":"R Shen","year":"2016","unstructured":"Shen, R. & Seshan, V. E. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 44, e131 (2016).","journal-title":"Nucleic Acids Res."},{"key":"10197_CR65","doi-asserted-by":"publisher","unstructured":"Jonsson, P. et al. Tumour lineage shapes BRCA-mediated phenotypes. Nature https:\/\/doi.org\/10.1038\/s41586-019-1382-1 (2019).","DOI":"10.1038\/s41586-019-1382-1"},{"key":"10197_CR66","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1038\/s41588-021-00949-1","volume":"53","author":"P Srinivasan","year":"2021","unstructured":"Srinivasan, P. et al. The context-specific role of germline pathogenicity in tumorigenesis. Nat. Genet. 53, 1577\u20131585 (2021).","journal-title":"Nat. Genet."},{"key":"10197_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-017-0271-4","volume":"10","author":"DT Cheng","year":"2017","unstructured":"Cheng, D. T. et al. Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing. BMC Med. Genomics 10, 33 (2017).","journal-title":"BMC Med. Genomics"},{"key":"10197_CR68","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/s41588-025-02187-1","volume":"57","author":"A Gupta","year":"2025","unstructured":"Gupta, A. et al. APOBEC3 mutagenesis drives therapy resistance in breast cancer. Nat. Genet. 57, 1452\u20131462 (2025).","journal-title":"Nat. Genet."},{"key":"10197_CR69","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s43018-020-0047-1","volume":"1","author":"P Razavi","year":"2020","unstructured":"Razavi, P. et al. Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. Nat. Cancer 1, 382\u2013393 (2020).","journal-title":"Nat. Cancer"},{"key":"10197_CR70","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1038\/s41591-019-0652-7","volume":"25","author":"P Razavi","year":"2019","unstructured":"Razavi, P. et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat. Med. 25, 1928\u20131937 (2019).","journal-title":"Nat. Med."},{"key":"10197_CR71","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.ccell.2024.09.009","volume":"42","author":"R Kudo","year":"2024","unstructured":"Kudo, R. et al. Long-term breast cancer response to CDK4\/6 inhibition defined by TP53-mediated geroconversion. Cancer Cell 42, 1919\u20131935.e9 (2024).","journal-title":"Cancer Cell"},{"key":"10197_CR72","first-page":"PO.17.00011","volume":"1","author":"D Chakravarty","year":"2017","unstructured":"Chakravarty, D. et al. OncoKB: a precision oncology knowledge base. JCO Precis. Oncol. 1, PO.17.00011 (2017).","journal-title":"JCO Precis. Oncol."},{"key":"10197_CR73","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/jnci\/djaa087","volume":"113","author":"B O\u2019leary","year":"2021","unstructured":"O\u2019leary, B. et al. Circulating tumor DNA markers for early progression on fulvestrant with or without palbociclib in ER+ advanced breast cancer. J. Natl Cancer Inst. 113, 309\u2013317 (2021).","journal-title":"J. Natl Cancer Inst."},{"key":"10197_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24109-5","volume":"12","author":"A Rose Brannon","year":"2021","unstructured":"Rose Brannon, A. et al. Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. Nat. Commun. 12, 3770 (2021).","journal-title":"Nat. Commun."},{"key":"10197_CR75","doi-asserted-by":"publisher","first-page":"e0140712","DOI":"10.1371\/journal.pone.0140712","volume":"10","author":"RB Lanman","year":"2015","unstructured":"Lanman, R. B. et al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PLoS ONE 10, e0140712 (2015).","journal-title":"PLoS ONE"},{"key":"10197_CR76","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1158\/1535-7163.1427.3.11","volume":"3","author":"DW Fry","year":"2004","unstructured":"Fry, D. W. et al. Specific inhibition of cyclin-dependent kinase 4\/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 3, 1427\u20131437 (2004).","journal-title":"Mol. Cancer Ther."},{"key":"10197_CR77","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1158\/2159-8290.CD-18-0830","volume":"10","author":"C Costa","year":"2020","unstructured":"Costa, C. et al. Pten loss mediates clinical cross-resistance to CDK4\/6 and PI3K\u03b1 inhibitors in breast cancer. Cancer Discov. 10, 72\u201385 (2020).","journal-title":"Cancer Discov."},{"key":"10197_CR78","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1158\/2159-8290.CD-20-1726","volume":"12","author":"Q Li","year":"2022","unstructured":"Li, Q. et al. INK4 tumor suppressor proteins mediate resistance to CDK4\/6 kinase inhibitors. Cancer Discov. 12, 356\u2013371 (2022).","journal-title":"Cancer Discov."},{"key":"10197_CR79","doi-asserted-by":"publisher","first-page":"105828","DOI":"10.1016\/j.ebiom.2025.105828","volume":"118","author":"MR Lloyd","year":"2025","unstructured":"Lloyd, M. R. et al. A bedside-to-bench translational analysis of NF1 alterations and CDK4\/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer. EBioMedicine 118, 105828 (2025).","journal-title":"EBioMedicine"},{"key":"10197_CR80","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1016\/j.celrep.2018.10.046","volume":"25","author":"W Shi","year":"2018","unstructured":"Shi, W. et al. Reliability of whole-exome sequencing for assessing intratumor genetic heterogeneity. Cell Rep. 25, 1446\u20131457 (2018).","journal-title":"Cell Rep."},{"key":"10197_CR81","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213\u2013219 (2013).","journal-title":"Nat. Biotechnol."},{"key":"10197_CR82","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1101\/gr.129684.111","volume":"22","author":"DC Koboldt","year":"2012","unstructured":"Koboldt, D. C. et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568\u2013576 (2012).","journal-title":"Genome Res."},{"key":"10197_CR83","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1093\/bioinformatics\/bts271","volume":"28","author":"CT Saunders","year":"2012","unstructured":"Saunders, C. T. et al. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics 28, 1811\u20131817 (2012).","journal-title":"Bioinformatics"},{"key":"10197_CR84","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1038\/nprot.2016.150","volume":"11","author":"H Fang","year":"2016","unstructured":"Fang, H. et al. Indel variant analysis of short-read sequencing data with Scalpel. Nat. Protoc. 11, 2529\u20132548 (2016).","journal-title":"Nat. Protoc."},{"key":"10197_CR85","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/ng.3036","volume":"46","author":"A Rimmer","year":"2014","unstructured":"Rimmer, A. et al. Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications. Nat. Genet. 46, 912\u2013918 (2014).","journal-title":"Nat. Genet."},{"key":"10197_CR86","doi-asserted-by":"publisher","DOI":"10.1093\/gigascience\/giab008","volume":"10","author":"P Danecek","year":"2021","unstructured":"Danecek, P. et al. Twelve years of SAMtools and BCFtools. Gigascience 10, giab008 (2021).","journal-title":"Gigascience"},{"key":"10197_CR87","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1004873","volume":"12","author":"E Talevich","year":"2016","unstructured":"Talevich, E., Shain, A. H., Botton, T. & Bastian, B. C. CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput. Biol. 12, e1004873 (2016).","journal-title":"PLoS Comput. Biol."},{"key":"10197_CR88","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1093\/bioinformatics\/btv710","volume":"32","author":"X Chen","year":"2016","unstructured":"Chen, X. et al. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics 32, 1220\u20131222 (2016).","journal-title":"Bioinformatics"},{"key":"10197_CR89","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1101\/gr.221028.117","volume":"28","author":"JA Wala","year":"2018","unstructured":"Wala, J. A. et al. SvABA: genome-wide detection of structural variants and indels by local assembly. Genome Res. 28, 581\u2013591 (2018).","journal-title":"Genome Res."},{"key":"10197_CR90","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1101\/gr.222109.117","volume":"27","author":"DL Cameron","year":"2017","unstructured":"Cameron, D. L. et al. GRIDSS: sensitive and specific genomic rearrangement detection using positional de Bruijn graph assembly. Genome Res. 27, 2050\u20132060 (2017).","journal-title":"Genome Res."},{"key":"10197_CR91","doi-asserted-by":"crossref","unstructured":"Chen, S. et al. Paragraph: a graph-based structural variant genotyper for short-read sequence data. Genome Biol. 20, 291 (2019).","DOI":"10.1186\/s13059-019-1909-7"},{"key":"10197_CR92","doi-asserted-by":"publisher","first-page":"3572","DOI":"10.1093\/bioinformatics\/bty304","volume":"34","author":"V Geoffroy","year":"2018","unstructured":"Geoffroy, V. et al. AnnotSV: an integrated tool for structural variations annotation. Bioinformatics 34, 3572\u20133574 (2018).","journal-title":"Bioinformatics"},{"key":"10197_CR93","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btad509","volume":"39","author":"T Moreno","year":"2023","unstructured":"Moreno, T., Magana, J. & Quigley, D. A. AARDVARK: an automated reversion detector for variants affecting resistance kinetics. Bioinformatics 39, btad509 (2023).","journal-title":"Bioinformatics"},{"key":"10197_CR94","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1158\/2159-8290.CD-17-0146","volume":"7","author":"D Quigley","year":"2017","unstructured":"Quigley, D. et al. Analysis of circulating cell-free DnA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors. Cancer Discov. 7, 999\u20131005 (2017).","journal-title":"Cancer Discov."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10197-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10197-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10197-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T23:11:35Z","timestamp":1776294695000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10197-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":94,"journal-issue":{"issue":"8110","published-print":{"date-parts":[[2026,4,16]]}},"alternative-id":["10197"],"URL":"https:\/\/doi.org\/10.1038\/s41586-026-10197-0","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"3 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.S. has received travel support from Novartis.\u00a0J.S.R.-F., M.S., E.N., N.L., E.S., S.R., M.R.A., A.D.S. and V.S. are currently employed by AstraZeneca. Y.L. and X.H. are currently employed by Pfizer. M.F.B. has received consultation from AstraZeneca, Eli Lilly and Paige AI; has received\u00a0research support from Boundless Bio; and declares intellectual property interests with SOPHiA Genetics. B.T.L. is a current employee and stockholder of AstraZeneca, and the research was conducted while he served as faculty at MSK; he has served as an uncompensated advisor and consultant to Amgen, AstraZeneca, Boehringer Ingelheim, Bolt Biotherapeutics, Daiichi Sankyo, Genentech and Lilly; has received research grants to his institution from Amgen, AstraZeneca, Bolt Biotherapeutics, Daiichi Sankyo, Genentech, Lilly, Nuvalent and Revolution Medicines; is an inventor on three institutional patents at MSK (US62\/685,057, US62\/514,661 and US63\/424,813); and has intellectual property rights as a book author at Karger Publishers and Shanghai Jiao Tong University Press. M.\u00a0Lee reports equity and professional services and activites from Biologica. S.C. has received institutional grants or funding from Daiichi Sankyo and AstraZeneca; share options in Totus Medicines; and consultation, ad board or honoraria from Daiichi Sankyo, AstraZeneca, Lilly, Casdin Capital, Merck and Pathos AI. P.R. has received institutional grants and\/or funding from Grail, Novartis, AstraZeneca, Invitae, Biothernostics, Tempus, Neogenomics, Guardant Health, Personalis, Myriad Genetics, Foresight Diagnostics, Natera, Biodesix, SAGA Diagnostics, SOPHiA Genetics, Haystack and Roche; and consultation, ad board or honoraria from Novartis, AstraZeneca, Lilly\/Loxo, Stemline Therapeutics, Prelude Therapeutics, Neogenomics, Regor Pharmaceuticals, SAGA Diagnostics, SOPHiA Genetics, Tempus, Myriad Genetics, Foresight Diagnostics, Natera, Pathos AI and BioNTech. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}